Wegovy Manufacturing, Supply & Shortage History

How Wegovy Works: Mechanism of Action

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds GLP-1 receptors in the hypothalamus, brainstem, pancreas, and gastrointestinal tract, reducing caloric intake, slowing gastric emptying, and improving insulin secretion in a glucose-dependent manner. The net clinical result is substantial, durable weight loss in patients with obesity or overweight with at least one weight-related comorbidity.

GLP-1 Receptor Binding and Appetite Suppression

Endogenous GLP-1 has a plasma half-life of roughly 2 minutes because dipeptidyl peptidase-4 (DPP-4) degrades it rapidly. Semaglutide carries a C-18 fatty-acid chain attached via a linker to lysine at position 26, allowing albumin binding and dramatically extending half-life to approximately 165 hours. That extended half-life supports once-weekly dosing [1].

Hypothalamic GLP-1 receptor activation reduces neuropeptide Y and agouti-related peptide signaling, the two primary hunger-driving pathways, while increasing pro-opiomelanocortin output. The result is lower appetite and reduced food-reward drive. A 2021 NEJM mechanistic commentary noted that central GLP-1 receptor agonism accounts for a larger share of weight loss than peripheral gastric effects alone [2].

Gastric Emptying and Glycemic Effects

Semaglutide slows gastric emptying, particularly in the early postprandial period, which blunts post-meal glucose excursions. This effect is more pronounced during the first weeks of treatment and attenuates slightly with chronic use, a finding confirmed in a pharmacodynamic sub-study of the SUSTAIN trial program [3]. Insulin secretion increases in a strictly glucose-dependent manner, meaning hypoglycemia risk is low when semaglutide is used as monotherapy.

Cardiovascular Mechanism

The SELECT trial (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg vs. Placebo over a mean 39.8 months in patients with established cardiovascular disease but without diabetes [4]. Anti-inflammatory effects on arterial endothelium, reductions in C-reactive protein, and improvements in blood pressure likely contribute, though the precise weighting of each mechanism remains under study.

STEP-1 and the Clinical Evidence That Drove Demand

The STEP-1 trial is the foundational efficacy dataset behind Wegovy's approval and the commercial surge that eventually overwhelmed supply. Understanding the trial helps explain why demand was so much larger than Novo Nordisk initially projected.

STEP-1 Primary Results

STEP-1 (N=1,961) randomized adults with BMI ≥30 kg/m² (or ≥27 with at least one weight-related comorbidity) to semaglutide 2.4 mg or placebo, both with lifestyle intervention, for 68 weeks. Semaglutide produced a mean body-weight reduction of 14.9% vs. 2.4% with placebo (P<0.001) [5]. Roughly 86.4% of semaglutide patients lost ≥5% of body weight vs. 31.5% on placebo.

What STEP-1 Did Not Predict

The trial's extraordinary effect size generated substantial media coverage beginning in early 2021, months before FDA approval. Prescription demand at launch in June 2021 outpaced any internal Novo Nordisk forecast built on prior GLP-1 analogs. The company publicly acknowledged in its Q3 2022 earnings call that Wegovy demand was "significantly above our initial expectations," a direct driver of the shortage that followed [6].

The full STEP clinical program included STEP-2 (type 2 diabetes, N=1,210), STEP-3 (intensive behavioral therapy, N=611), and STEP-4 (withdrawal-and-maintenance design, N=803), all published in peer-reviewed journals [7]. Each showed clinically meaningful weight loss, amplifying prescriber and patient interest simultaneously.

The Manufacturing Process Behind Semaglutide 2.4 mg

Producing a GLP-1 receptor agonist peptide at commercial scale is among the most technically demanding tasks in pharmaceutical manufacturing. Several structural features of semaglutide make scale-up particularly challenging.

Peptide Synthesis Complexity

Semaglutide is a 31-amino-acid peptide with a site-specific fatty-acid modification. It is manufactured via solid-phase peptide synthesis (SPPS) followed by high-performance liquid chromatography (HPLC) purification steps. Each synthesis cycle introduces the possibility of deletion sequences, racemization, or incomplete coupling. Even at high-volume synthesis sites, batch failure rates for complex modified peptides can reach 5-15%, consuming raw material and time [8].

The fatty-acid linker attached to lysine-26 requires a separate conjugation step under controlled conditions. That step adds both process time and potential yield loss. The entire active pharmaceutical ingredient (API) manufacturing sequence typically requires 6 to 9 months from raw amino acids to a released API batch, before any formulation or fill-finish work begins.

Fill-Finish and Device Assembly

Wegovy is supplied in a prefilled auto-injector pen. Fill-finish operations (sterile filtration, filling into cartridges, and assembly into pens) require pharmaceutical-grade cleanroom environments meeting FDA aseptic processing standards outlined in 21 CFR Part 211 [9]. Device assembly introduces a separate validation burden: each pen component, from the needle cap to the dose counter, must meet tolerances specified in the 510(k) device dossier.

Novo Nordisk operates fill-finish lines primarily at its Chartres, France facility and at its Kalundborg, Denmark API campus. The company has disclosed capital expenditure of more than DKK 40 billion (approximately USD 5.8 billion) committed to capacity expansion between 2022 and 2026, directed at both API synthesis and fill-finish lines across Denmark, France, and the United States [10].

Cold Chain and Logistics

Wegovy requires refrigerated storage at 2-8°C. Cold-chain constraints compound supply problems when distribution networks are already stretched. A single temperature excursion event can render an entire shipment non-releasable. The FDA's guidance on temperature-sensitive drug products outlines the release-testing requirements that apply [11].

FDA Shortage History: Timeline and Regulatory Actions

The FDA maintains an official drug shortage database. Wegovy has a documented and publicly traceable shortage history that spans more than two years.

Initial Shortage Declaration (March 2022)

The FDA first added Wegovy 0.25 mg/dose and 0.5 mg/dose injection pens to its shortage database in March 2022, less than nine months after approval [12]. These starter doses are medically necessary because the label requires a 16-week escalation before reaching the 2.4 mg maintenance dose. Shortage at the 0.25 mg level effectively blocked new patient starts entirely, since patients cannot safely initiate at 2.4 mg.

Escalation to All Dose Strengths (Mid-2022)

By August 2022, all five Wegovy dose strengths (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) appeared on the FDA shortage list [12]. At that point the agency formally classified the situation as an "active shortage," triggering the regulatory provisions that permit compounding pharmacies to produce copies of shortage-listed drugs under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act [13].

Compounded Semaglutide Market

Once semaglutide appeared on the FDA shortage list, both 503A compounding pharmacies (patient-specific, prescription-based) and 503B outsourcing facilities (larger batch compounders) began producing semaglutide for weight loss. The FDA issued multiple safety alerts between 2023 and 2024 warning that compounded semaglutide products had caused hospitalizations, largely due to dosing errors from non-standardized concentration vials [14].

The American Society of Health-System Pharmacists (ASHP) shortage database tracked semaglutide as continuously short from mid-2022 through at least Q1 2024 [15].

FDA Removal from Shortage List (May 2024)

In May 2024, the FDA determined that Wegovy supply had sufficiently recovered to remove semaglutide 2.4 mg from the active shortage database [12]. That decision triggered a wind-down period for compounding: 503B facilities received a deadline of October 2024 to cease production, and 503A pharmacies faced a subsequent deadline. Novo Nordisk supported the FDA's removal decision and confirmed in its H1 2024 financial report that U.S. Supply was meeting current demand [10].

Several 503B outsourcing facilities challenged the FDA's removal decision, arguing that supply remained insufficient in certain dose strengths and geographic areas. The FDA declined to reverse the removal [16].

Ongoing Access Gaps

Removal from the shortage list does not mean every patient can fill a prescription. Insurance coverage remains the dominant access barrier. As of 2024, fewer than 25% of commercial health plans covered Wegovy without step-therapy requirements, and Medicare Part D explicitly excluded weight-loss drugs until the potential passage of the Treat and Reduce Obesity Act, which remained in legislative discussion as of mid-2025 [17]. Out-of-pocket cost without insurance runs approximately USD 1,300-1,400 per month at retail pharmacy pricing.

Novo Nordisk's Capacity Expansion Strategy

Novo Nordisk has treated the Wegovy supply crisis as a multi-year capital project rather than a short-term logistics fix.

Hjortekaer and Kalundborg Expansions

The company's Kalundborg, Denmark facility is the primary global API production site for semaglutide. Novo Nordisk has added fermentation and synthesis capacity there in stages since 2022. Separately, the company acquired a fill-finish facility in Søborg, Denmark and converted it to support Ozempic and Wegovy pen production [10].

Chartres, France Investment

The Chartres facility handles a significant portion of Wegovy fill-finish for the European and U.S. Markets. Novo Nordisk committed EUR 2.1 billion in additional Chartres investment through 2025, focusing on sterile filling lines capable of handling the auto-injector format [10].

U.S. Manufacturing Footprint

Novo Nordisk announced a USD 4.1 billion investment in a new manufacturing campus in Clayton, North Carolina in June 2024. The Clayton site will produce fill-finish for injectable diabetes and obesity products, with production expected to begin no earlier than 2027 [10]. A separate agreement with contract manufacturer Catalent (since acquired by Novo Nordisk) added additional fill-finish capacity for the U.S. Market.

The table below summarizes the staged capacity expansion and its projected effect on U.S. Wegovy supply. This framework was developed by the HealthRX medical and policy team using Novo Nordisk investor disclosures and FDA shortage database records.

| Phase | Timeline | Action | Projected U.S. Supply Effect | |---|---|---|---| | Phase 1 | Q3 2022 - Q2 2023 | Kalundborg API line additions | Partial relief at starter doses | | Phase 2 | Q3 2023 - Q2 2024 | Chartres fill-finish expansion | All doses available, limited allocation | | Phase 3 | Q3 2024 - 2025 | Catalent/Novo fill-finish integration | Full U.S. Dose availability | | Phase 4 | 2027+ | Clayton NC campus online | Domestic redundancy, reduced cold-chain risk |

Why the Shortage Hit Starter Doses Hardest

A pharmacoeconomically counterintuitive feature of the Wegovy shortage was that the 0.25 mg and 0.5 mg pens ran out before higher doses. Two structural factors explain this.

Single-Patient Consumption Pattern

Every new patient starts with four weeks of 0.25 mg, then four weeks of 0.5 mg, before advancing. A single patient consumes one pen of each starter dose before they ever need a maintenance dose pen. Novo Nordisk initially calibrated production ratios to steady-state maintenance demand, underweighting the starter-dose inventory needed for a rapidly expanding new-patient cohort. When new prescriptions tripled in Q1 and Q2 of 2022 following media attention, starter-dose inventory collapsed first [6].

Formulary and Specialty Pharmacy Allocation

Specialty pharmacies received allocation priority for higher doses to protect existing maintenance patients. That rational short-term decision deepened the starter-dose gap. New patients could not initiate therapy even when 1.7 mg or 2.4 mg pens were technically available somewhere in the distribution chain.

Semaglutide Beyond Wegovy: Supply Overlap with Ozempic

Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) shares API manufacturing infrastructure with Wegovy. Both drugs use the same molecule; the difference is dose and indication. When Wegovy demand surged, Novo Nordisk faced difficult allocation decisions between its diabetes and obesity franchises.

The FDA's 2023 drug shortage guidance explicitly discourages manufacturers from diverting supply between indications in ways that harm one patient population to benefit another [11]. Ozempic also appeared intermittently on the FDA shortage database through 2023, and the American Diabetes Association expressed concern that diabetes patients were losing access to semaglutide while it was being prescribed off-label for weight loss [18].

A 2023 JAMA Internal Medicine analysis of pharmacy claims data found that semaglutide prescriptions for weight loss in non-diabetic patients increased 400% between January 2021 and December 2022, a rate that exceeded any realistic supply expansion timeline [19].

Safety Signals Emerging From the Shortage Period

The shortage itself created safety risks beyond simple access loss.

Compounding Errors and Hospitalizations

The FDA's MedWatch system received reports of hypoglycemia, nausea-related dehydration, and pancreatitis in patients using compounded semaglutide between 2022 and 2024. A July 2023 FDA safety alert specifically cited incorrect dosing from vials requiring patient self-calculation, compared to the fixed-dose pens of branded Wegovy [14]. Multiple reports involved 10-fold dosing errors.

Dose Interruptions in Existing Patients

Patients forced off Wegovy due to supply interruptions can experience rapid weight regain. The STEP-4 withdrawal trial (N=803) showed that patients who discontinued semaglutide after 20 weeks regained two-thirds of their lost weight within one year of stopping [20]. Supply gaps therefore carry direct clinical cost for patients who had achieved therapeutic weight loss.

Current Status and 2025 Outlook

As of mid-2025, all five Wegovy dose strengths are listed as available by Novo Nordisk and are not on the FDA active shortage database [12]. Retail pharmacy fill rates have improved substantially. GoodRx and industry pharmacy benefit data suggest that 90-day fill rates for Wegovy reached approximately 78% in Q4 2024, compared to under 40% during the peak shortage period in late 2022.

The FDA's updated semaglutide shortage policy requires Novo Nordisk to submit quarterly supply and demand reports under the enhanced drug shortage reporting requirements codified in the FDA Safety and Innovation Act [21]. That reporting obligation adds transparency that was absent during the initial shortage period.

Insurance coverage expansion remains the outstanding structural barrier. The Obesity Care Advocacy Network has documented that even with full supply, over 60% of commercially insured U.S. Adults lack coverage for GLP-1 medications for obesity [17]. Clinicians prescribing Wegovy should confirm active insurance coverage and pharmacy stock before initiating the dose-escalation sequence, since a forced interruption during escalation carries both clinical and cost risks for patients.